| __timestamp | Amneal Pharmaceuticals, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 10337679 |
| Thursday, January 1, 2015 | 109679000 | 18187286 |
| Friday, January 1, 2016 | 118757000 | 24758063 |
| Sunday, January 1, 2017 | 109046000 | 23666957 |
| Monday, January 1, 2018 | 230435000 | 30099855 |
| Tuesday, January 1, 2019 | 289598000 | 64947625 |
| Wednesday, January 1, 2020 | 326727000 | 186363444 |
| Friday, January 1, 2021 | 365504000 | 272611040 |
| Saturday, January 1, 2022 | 399700000 | 358782000 |
| Sunday, January 1, 2023 | 429675000 | 409864000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, understanding cost structures is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Amneal Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Amneal Pharmaceuticals saw a steady increase in SG&A expenses, peaking at approximately 430 million in 2023, a fivefold increase from 2014. Intra-Cellular Therapies, on the other hand, experienced a dramatic rise, with expenses surging nearly 40 times from 2014 to 2023, reaching around 410 million. This stark contrast highlights differing strategic approaches: Amneal's consistent growth versus Intra-Cellular's rapid expansion. Such insights are invaluable for investors and industry analysts seeking to understand the financial dynamics and strategic priorities of these pharmaceutical giants.
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Intra-Cellular Therapies, Inc.
Selling, General, and Administrative Costs: Zoetis Inc. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Genmab A/S and Amneal Pharmaceuticals, Inc.
Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Blueprint Medicines Corporation or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Amneal Pharmaceuticals, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Vericel Corporation